We have identified a list of several trending healthtech stocks that appear have recently received buy ratings from top Wall Street analysts and are showing positive investor sentiment, as well as news headlines. With that said, our editors here at healthtechmovers.com, are adding these healthtech companies to our watchlist to see if this momentum continues. Our watchlist includes trending
Summary: Gritstone Oncology is developing tumor-specific cancer immunotherapies to fight multiple cancer types. The company has built its tumor-specific immunotherapy approach on two key pillars - first, a proprietary machine learning-based platform, Gritstone EDGE(TM), which provides a powerful ability to predict from a routine tumor biopsy the tumor-specific neoantigens, or TSNA, that are presented on a patient's tumor cells; and second, the ability to develop and manufacture potent immunotherapies utilizing patients' TSNA to drive the patient's immune system to attack and destroy tumors.
- Recent GRTS Stock Price: $2.08
- Yearly Gain for GRTS stock: -22.96%
- Market Cap for GRTS stock: $198.31M
- P/E Ratio for GRTS stock: -1.68
Will GRTS's stock price go up? Is there an accurate GRTS stock forecast available?
TipRanks.com reports that Gritstone bio, Inc. currently has 5 analysts offering 12-month price targets and the consensus is a Buy rating with an average price target is $10.00. The target pricing ranges from a high GRTS forecast of $7 down to a low forecast of $10. Gritstone bio, Inc. (GRTS)’s last closing stock price was $2.08 which would put the average price target at 380.77% upside.
In addition, TradingView issued a Sell rating for GRTS stock over the next month, Barchart.com has a buy rating and Yahoo! Finance has a Neutral short-term outlook. Remember, securities are volatile, so please do your own research on GRTS stock.
Other analysts covering GRTS include:
- Mayank Mamtani of B.Riley Financial issued a Buy rating with the price target of $6 on 17 hours ago
- Kaveri Pohlman of BTIG issued a Buy rating with the price target of $20 on 1 day ago
- Catherine Novack of JonesTrading issued a Buy rating with the price target of $10 on 1 month ago
- Edward Tenthoff of Piper Sandler issued a Buy rating with the price target of $7 on 3 months ago
If you are wondering if GRTS is a good stock to buy, here are 3rd party ratings for GRTS stock:
- TipRanks.com: Buy
- TradingView.com: Sell
- Yahoo! Finance: Neutral Short-Term Outlook
- Barchart.com: buy
- Zacks.com: Hold, Top 36% (91 out of 250)
What is the sentiment on the street regarding Gritstone bio, Inc.? (Current ratings compiled by TipRanks.com)
- News Sentiment for GRTS stock: Bearish
- Blogger Consensus for GRTS stock:
- Media Buzz for GRTS stock: Neutral
- Insider Signal for GRTS stock: Selling
- Investor Sentiment for GRTS stock: Positive
- Hedge Fund signal for GRTS stock: High Risk
The stock market is extremely volatile, and you need to do your own research on GRTS stock including scouring the social networks like GRTS StockTwits, Twitter and Reddit before you decide to make any investment.
Click here for GRTS stock chart >>
Summary: G1 Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It engaged in developing novel, small-molecule therapies which address significant unmet needs in the treatment of cancer. The company's product pipeline consists of CDK4/6, Trilaciclib (G1T28), G1T38 and G1T48. G1 Therapeutics, Inc. is based in Research Triangle Park, NC.
- Recent GTHX Stock Price: $2.10
- Yearly Gain for GTHX stock: -37.13%
- Market Cap for GTHX stock: $108.87M
- P/E Ratio for GTHX stock: -1.47
Will GTHX's stock price go up? Is there an accurate GTHX stock forecast available?
TipRanks.com reports that G1 Therapeutics, Inc. currently has 3 analysts offering 12-month price targets and the consensus is a Buy rating with an average price target is $8.33. The target pricing ranges from a high GTHX forecast of $9 down to a low forecast of $12. G1 Therapeutics, Inc. (GTHX)’s last closing stock price was $2.10 which would put the average price target at 296.83% upside.
In addition, TradingView issued a Strong sell rating for GTHX stock over the next month, Barchart.com has a Weak buy rating and Yahoo! Finance has a Bearish short-term outlook. Remember, securities are volatile, so please do your own research on GTHX stock.
Other analysts covering GTHX include:
- Gil Blum of Needham issued a Buy rating with the price target of $12 on 17 hours ago
- Edward White of H.C. Wainwright issued a Buy rating with the price target of $9 on 17 hours ago
If you are wondering if GTHX is a good stock to buy, here are 3rd party ratings for GTHX stock:
- TipRanks.com: Buy
- TradingView.com: Strong sell
- Yahoo! Finance: Bearish Short-Term Outlook
- Barchart.com: Weak buy
- Zacks.com: Hold, Top 36% (91 out of 250)
What is the sentiment on the street regarding G1 Therapeutics, Inc.? (Current ratings compiled by TipRanks.com)
- News Sentiment for GTHX stock: Bullish
- Blogger Consensus for GTHX stock:
- Media Buzz for GTHX stock: Sell
- Insider Signal for GTHX stock: Selling
- Investor Sentiment for GTHX stock: Positive
- Hedge Fund signal for GTHX stock: High Risk
The stock market is extremely volatile, and you need to do your own research on GTHX stock including scouring the social networks like GTHX StockTwits, Twitter and Reddit before you decide to make any investment.
Click here for GTHX stock chart >>
Summary: Repare Therapeutics Inc. is an oncology company. It utilizes genome-wide, CRISPR-enabled SNIPRx(R) platform to discover and develop targeted cancer therapies focused on genomic instability, including DNA damage repair. The Company's product pipeline includes RP-3500, which is in clinical stage. Repare Therapeutics Inc. is based in St-Laurent, Canada.
- Recent RPTX Stock Price: $7.10
- Yearly Gain for RPTX stock: -39.68%
- Market Cap for RPTX stock: $299.12M
- P/E Ratio for RPTX stock: -3.07
Will RPTX's stock price go up? Is there an accurate RPTX stock forecast available?
TipRanks.com reports that Repare Therapeutics Inc. currently has 5 analysts offering 12-month price targets and the consensus is a Buy rating with an average price target is $18.20. The target pricing ranges from a high RPTX forecast of $8 down to a low forecast of $12. Repare Therapeutics Inc. (RPTX)’s last closing stock price was $7.10 which would put the average price target at 156.34% upside.
In addition, TradingView issued a Neutral rating for RPTX stock over the next month, Barchart.com has a Weak buy rating and Yahoo! Finance has a Bullish short-term outlook. Remember, securities are volatile, so please do your own research on RPTX stock.
Other analysts covering RPTX include:
- Benjamin Burnett of Stifel Nicolaus issued a Buy rating with the price target of $12 on 17 hours ago
- Tim Chiang of Capital One Financial issued a Buy rating with the price target of $21 on 1 day ago
- Robert Burns of H.C. Wainwright issued a Buy rating with the price target of $25 on 2 weeks ago
- Jeffrey Hung of Morgan Stanley issued a Hold rating with the price target of $8 on 1 month ago
If you are wondering if RPTX is a good stock to buy, here are 3rd party ratings for RPTX stock:
- TipRanks.com: Buy
- TradingView.com: Neutral
- Yahoo! Finance: Bullish Short-Term Outlook
- Barchart.com: Weak buy
- Zacks.com: Buy, Top 36% (91 out of 250)
What is the sentiment on the street regarding Repare Therapeutics Inc.? (Current ratings compiled by TipRanks.com)
- News Sentiment for RPTX stock: Bearish
- Blogger Consensus for RPTX stock:
- Media Buzz for RPTX stock: Neutral
- Insider Signal for RPTX stock: Buying
- Investor Sentiment for RPTX stock: Negative
- Hedge Fund signal for RPTX stock: High Risk
The stock market is extremely volatile, and you need to do your own research on RPTX stock including scouring the social networks like RPTX StockTwits, Twitter and Reddit before you decide to make any investment.
Click here for RPTX stock chart >>
Summary: Larimar Therapeutics Inc. is a clinical-stage biotechnology company. It is focused on developing treatments for rare diseases. The company's lead product consist CTI-1601, which is in clinical stage. Larimar Therapeutics Inc., formerly known as Zafgen Inc., is based in BALA CYNWYD, Pa.
- Recent LRMR Stock Price: $8.74
- Yearly Gain for LRMR stock: 38.51%
- Market Cap for LRMR stock: $383.74M
- P/E Ratio for LRMR stock: -14.57
Will LRMR's stock price go up? Is there an accurate LRMR stock forecast available?
TipRanks.com reports that Larimar Therapeutics, Inc. currently has 4 analysts offering 12-month price targets and the consensus is a Buy rating with an average price target is $18.50. The target pricing ranges from a high LRMR forecast of $25 down to a low forecast of $10. Larimar Therapeutics, Inc. (LRMR)’s last closing stock price was $8.74 which would put the average price target at 111.67% upside.
In addition, TradingView issued a Strong buy rating for LRMR stock over the next month, Barchart.com has a Strong buy rating and Yahoo! Finance has a Bullish short-term outlook. Remember, securities are volatile, so please do your own research on LRMR stock.
Other analysts covering LRMR include:
- Yatin Suneja of Guggenheim issued a Buy rating with the price target of $25 on 1 day ago
- Samantha Semenkow of Citi issued a Buy rating with the price target of $10 on 1 day ago
- Cory Jubinville, PhD of LifeSci Capital issued a Buy rating with the price target of $14 on 2 months ago
If you are wondering if LRMR is a good stock to buy, here are 3rd party ratings for LRMR stock:
- TipRanks.com: Buy
- TradingView.com: Strong buy
- Yahoo! Finance: Bullish Short-Term Outlook
- Barchart.com: Strong buy
- Zacks.com: Hold, Top 34% (85 out of 250)
What is the sentiment on the street regarding Larimar Therapeutics, Inc.? (Current ratings compiled by TipRanks.com)
- News Sentiment for LRMR stock: Bearish
- Blogger Consensus for LRMR stock:
- Media Buzz for LRMR stock: Neutral
- Insider Signal for LRMR stock: Selling
- Investor Sentiment for LRMR stock: Positive
- Hedge Fund signal for LRMR stock: Medium Risk
The stock market is extremely volatile, and you need to do your own research on LRMR stock including scouring the social networks like LRMR StockTwits, Twitter and Reddit before you decide to make any investment.
Click here for LRMR stock chart >>
One resource you need to consider using Tipranks.com where as a premium member you get access to all buy ratings, price targets and insider trading signals. TipRanks.com tracks and measures the performance of over 50,000 financial experts. The TipRanks Star Ranking TM is calculated based on expert success rate, average return and statistical significance. Get more from TipRanks.com here >>
The Editor, HealthTechMovers.com
HealthTechMovers.com (HTM) is built for investors who are interested in healthcare stocks, health insurance stocks, healthcare technology stocks, biotechnology stocks, pharmaceutical stocks, healthcare service provider stocks, life science stocks and more. HTM aggregates market data from top tier financial content providers like Barchart.com, Tipranks.com, TradingView.com, Yahoo! Finance, and Zacks.com. The research and editorial team behind HTM consolidates this aggregated data into easily consumable reports used to produce articles, newsletters, and web content. The reports produced by HTM contain timely information stock analysis, stock price targets, earnings announcements, insider trades, dividends, and top moving stocks.
Disclaimer: Sandpiper Marketing Group, LLC would like to remind you the data contained in this website is not necessarily real-time nor accurate. All stocks, indexes, futures and Forex prices are not provided by exchanges but rather by our editor research at the time of writing this release, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Sandpiper Marketing does not bear any responsibility for any trading losses you might incur as a result of using this data. Sandpiper Marketing Group, LLC or anyone involved with Sandpiper Marketing Group, LLC will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in this website/newsletter is not trustworthy unless verified by their own research. Also, because events/circumstances frequently do not occur as expected, there will likely be differences between any predictions and actual results. Always consult a real licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.
==============================================================================